Slide 1: Report 9M 2025 Faes Farma
REPORT 9M 2025 Faes Farma
Slide 2: Index
INDEX 1/ Highlights and key figures 2/ Business evolution 9M 2025 3/ 9M 2025 results and outlook
Slide 3: Highlights and key figures
1/ Highlights and key figures
Slide 4: Highlights 9M 2025
HIGHLIGHTS AND KEY FIGURES 9M 2025 Highlights 9M 2025 / Total revenues +15.5% (+10,6% excluding M&A), in the high guidance range, driven by growth in all business areas. BUSINESS / Pharma revenues +13%, with the LATAM market (+16%) and Licences (+17%) being the main growth drivers. / Adjusted EBITDA
Slide 5: Key figures 9M 2025
HIGHLIGHTS AND KEY FIGURES 9M 2025 Key figures 9M 2025 Income EBITDA 454.0 M€ 106.5 M€ +15.5% -2.7% Income Top 3 molecules Adjusted EBITDA* 176.7 M€ 112.8 M€ +15.1% +3.0% Pharma revenues Net Profit 399.5 M€ 73.6 M€ +13.4% -7.6% *Adjusted EBITDA: ex M&A and exluiding extraordinary costs from Derio 5
Slide 6: Business evolution 9M 2025
2/ Business evolution 9M 2025
Slide 7: Balanced growth across all areas of the Group
Business evolution 9M 2025 Balanced growth across all areas of the Group Revenues by porfolio line Revenues by portfolio line 9M 2025 9M 2024 % 13% Animal nutrition and health Pharma 399.5 352.4 13% 39% Pharma top 3 molecules 176.7 153.5 15% Top 3 molecules Rest of Pharma 222.8 198.9 12% Animal Nutr
Slide 8: Highlights of the main molecules
Business evolution 9M 2025 Highlights of the main molecules Very positive evolution with excellent performance in both direct sales and Licences Bilastine The strong performance we saw in the first half of the year continues, with growth of +11% and 112.4 M€ positive results in all areas, particular
Slide 9: All business areas trending positive
Business evolution 9M 2025 All business areas trending positive Revenues by business area Revenues by business area 9M 2025 9M 2024 % 13% Animal nutrition and health Pharma 399.5 352.4 13% Pharma Iberia 170.7 158.1 8% 38% Pharma International (without licenses) 129.6 109.2 9% Pharma Iberia Pharma Li
Slide 10: Pharma business, solid growth in all lines
Business evolution 9M 2025 Pharma Pharma business, solid growth in all lines Pharma’s revenues evolution in M€ Total Pharma revenues: 399.5 M€ +13% Iberia* +8% 170.7 /01 158.1 IBERIA +8% Growth sustained mainly by prescription. The incorporation in June of Laboratorio Edol, offset part of the slowdo
Slide 11: Pharma Iberia, sustained growth in prescription
Business evolution 9M 2025 Pharma Pharma Iberia, sustained growth in prescription Iberia revenues: 170.7 M€ +8% Revenues of Pharma Iberia in M€ /01 Spain SPAIN +1% +1% 133.3 Prescription grew +4% with positive evolution especially in bilastine 132.1 +11% thanks to new formats and the respiratory fra
Slide 12: Pharma International, Latam as the growth engine
Business evolution 9M 2025 Pharma Pharma International, Latam as the growth engine International revenues: 129.6 M€, +19% Revenues of Pharma International in M€ /01 LATAM +16% LATAM +16% 83.8 72 Colombia +25%, Ecuador +31% and Peru +25% y México +19% continued to perform very positively, with strong
Slide 13: Licences
Business evolution 9M 2025 Pharma Licences Licences revenues: 99.2 M€ +17% Licences revenues in M€ /01 BILASTINE +8% Bilastine 70.3 +8% 76.3 Bilastine maintains the solid growth rate seen in previous quarters. The main drivers continue to be Eastern Europe and Asia-Pacific. /02 9M 2024 9M 2025 OTHER
Slide 14: Animal nutrition and health
Business evolution 9M 2025 Farm Animal nutrition and health FARM Faes revenues in M€ FARM Faes revenues: 57.8 M€ +48% /01 Significant growth in revenue, with the ISF business as the main driver, with revenue +48% 57.8 continuing to exceed expectations. 39.1 FARM Faes strengthens its leadership in an
Slide 15: Results and outlook
af FAES FARMA Results and outlook emia
Slide 16: P&L Highlights 9M 2025
RESULTS AND OUTLOOK P&L Results Thousand € 9M 2025 9M 2024 %change Ordinary income (sales) 440,953 379,535 16.2% Highlights 9M 2025 Other operating income 13,046 13,381 -2.5% Tota Income 453,998 392,916 15.5% /01 – Income Cost of sales -153,572 -122,679 25.2% Double-digit growth in the high end of t
Slide 17: Guides 2025 vs 9M 2025
RESULTS AND OUTLOOK Guides 2025 vs 9M 2025 Income 2025 Income 9M 2025 +8/10% +15.5% +10.6% excl. M&A EBITDA 2025 EBITDA 9M 2025 -6/-9% -2.7% Adjusted EBITDA* 2025 Adjusted EBITDA* 9M 2025 +3/5% +3.0% *Adjusted EBITDA: ex M&A and exluiding extraordinary costs from Derio 17
Slide 18: Q&A
af FAES FARMA ofp ens FAT Q&A
Slide 19: Disclaimer
DISCLAIMER This presentation has been prepared and published by Faes Pharma Group for information purposes only. This presentation does not constitute a prospectus or an offer or recommendation to invest. This presentation does not constitute a commitment to subscribe, an offer of financing or an of
Slide 20: Appendix
Appendix INCOME PHARMA IBERIA INCOME INTERNACIONAL (without licences) INCOME LICENCES INCOME FARM FAES 9M 2025 9M 2024* % var 9M 2025 9M 2024* % var 9M 2025 9M 2024* % var 9M 2025 9M 2024* % var Pharma Spain 133.3 132.1 1% International 129.6 109.3 19% Licences 99.2 85.1 17% Animal health and nutrit